Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Gomm, Willya | von Holt, Klausa | Thomé, Friederikea | Broich, Karlb | Maier, Wolfganga; c | Weckbecker, Klausd | Fink, Annea; e | Doblhammer, Gabrielea; e; f; g | Haenisch, Brittaa; *
Affiliations: [a] German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany | [b] Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany | [c] Department of Psychiatry, University of Bonn, Bonn, Germany | [d] Department of General Practice and Family Medicine, University of Bonn, Bonn, Germany | [e] Rostock Center for the Study of Demographic Change, Rostock, Germany | [f] Max-Planck-Institute for Demographic Research, Rostock, Germany | [g] Institute for Sociology and Demography, University of Rostock, Rostock, Germany
Correspondence: [*] Correspondence to: Britta Haenisch, PhD, German Center for Neurodegenerative Diseases (DZNE), c/o Federal Institute for Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger-Allee 3, D-53175 Bonn, Germany. Tel.: +49 228 99307 5721; Fax: +49 228 207 5765; E-mail: [email protected].
Abstract: Background: While acute detrimental effects of benzodiazepine (BDZ), and BDZ and related z-substance (BDZR) use on cognition and memory are known, the association of BDZR use and risk of dementia in the elderly is controversially discussed. Previous studies on cohort or claims data mostly show an increased risk for dementia with the use of BDZs or BDZRs. For Germany, analyses on large population-based data sets are missing. Objective: To evaluate the association between regular BDZR use and incident any dementia in a large German claims data set. Methods: Using longitudinal German public health insurance data from 2004 to 2011 we analyzed the association between regular BDZR use (versus no BDZR use) and incident dementia in a case-control design. We examined patient samples aged≥60 years that were free of dementia at baseline. To address potential protopathic bias we introduced a lag time between BDZR prescription and dementia diagnosis. Odds ratios were calculated applying conditional logistic regression, adjusted for potential confounding factors such as comorbidities and polypharmacy. Results: The regular use of BDZRs was associated with a significant increased risk of incident dementia for patients aged≥60 years (adjusted odds ratio [OR] 1.21, 95% confidence interval [CI] 1.13–1.29). The association was slightly stronger for long-acting substances than for short-acting ones. A trend for increased risk for dementia with higher exposure was observed. Conclusion: The restricted use of BDZRs may contribute to dementia prevention in the elderly.
Keywords: Benzodiazepines, dementia, elderly, risk factor, z-substances
DOI: 10.3233/JAD-151006
Journal: Journal of Alzheimer's Disease, vol. 54, no. 2, pp. 801-808, 2016
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]